BioNTech Results Presentation Deck

Clinical Strategy Supports Boosters and Platform Approach to Variants Clinical data supports a booster dose of the vaccine in adults or high risk populations to augment vaccine protection over time Clinical Trials Evaluating Booster Dose For Immunogenicity, Reactogenicity and Vaccine Efficacy 14 1 BNT162b2: 3rd dose Trials Evaluating Variant-Encoding Vaccines Support Flexible Platform Approach to Product Adaptation Safety & immunogenicity trial N=23 (Ph 1); N=~300 (Ph 2/3) First data published ¹ To date, no clinical evidence to advocate need to change vaccine to variant-specific version of vaccine. Platform approach preemptively prepares for the need, should it arise with a more severe/transmissible variant of concern. 3 Beta Variant-Encoding Vaccine: 3rd dose or naïve Safety & immunogenicity trial N=~300 (Ph 3); N=~300 (naïve) 2 BNT162b2: 3rd Dose Safety & Vaccine Efficacy trial N=~10,000 (Ph 3) Data in Q4 2021 Data in Q1 2022 4 Multivalent Delta + Alpha or Delta or Alpha Variant-Encoding Vaccines as 3rd dose or in naïve subjects Safety & immunogenicity trial N=~600; N= 300 (naïve) Data in Q4 2021 BIONTECH

View entire presentation